EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

To evaluate the efficacy of IVO compounds, the bleomycin-induced pulmonary fibrosis model in C57BL/6J mice, the most well-characterized and widely used preclinical model of IPF, will be used. Bleomycin administration results in reproducible pulmonary inflammation followed by fibrotic remodeling, leading to functional impairments that recapitulate key aspects of human IPF.